Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8XN4A)

• Drug Name: INCAGN1876 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DM8XN4A

Molecule-Related Drug Atlas

Drug(s) Targeting Activation-inducible TNFR family receptor (TNFRSF18)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
INCAGN01876	DMNUXKA	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
TRX-518	DMQS5DY	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
MK-4166	DML5V76	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
REGN6569	DM0ZMNI	Squamous head and neck cell carcinom	2D60.0	Phase 1	[5]
AMG 228	DMLQJ5P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
TRX518	DM9IDUH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
ASP1951	DMX4PWV	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Activation-inducible TNFR family receptor (TNFRSF18)	TTG6LA7	TNR18_HUMAN	Agonist	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of Agenus.
• [3] Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5.
• [4] Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5.
• [5] Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
• [6] Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. J Immunother Cancer. 2018 Sep 25;6(1):93.
• [7] Clinical pipeline report, company report or official report of Leap Therapeutics.
• [8] ClinicalTrials.gov (NCT03799003) A Study of ASP1951 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.